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During 1994–2005, we isolated Mycobacterium microti 
from 5 animals and 4 humans. Only 1 person was immuno-
compromised. Spoligotyping showed 3 patterns: vole type, 
llama type, and a new variant llama type.
N
aturally occurring mycobacteria that are part of the 
Mycobacterium tuberculosis complex include M. tu-
berculosis, M. bovis, M. caprae, M. africanum, M. microti, 
and M. pinnipedii. Although these species show remark-
able genetic homology, there are notable phenotypic differ-
ences, particularly in their relative pathogenicity for differ-
ent mammalian species.
Tuberculosis in wild rodents was ﬁ  rst studied in 1937 
as part of an investigation of cyclical changes in the popu-
lation density of voles (1). Field voles, bank voles, wood 
mice, and shrews are particularly susceptible to infec-
tion with M. microti (2). However, other small mammals 
such as guinea pigs, rabbits, mice, and rats are resistant to 
M.microti infection, even at high doses of infection. More 
recently, sporadic cases have been described in larger 
mammals (3–6).
There have been only 6 published reports of human 
infections, comprising 13 patients in total (7–11). Salient 
information from these reports is summarized in Table 1.
M. microti has been used in extensive trials to assess 
its efﬁ  cacy and safety as a vaccine. Percutaneously admin-
istered M. microti vaccine was found to be safe but no more 
effective than M. bovis BCG (12). The low virulence and 
poor immunogenicity are due to several key genetic dele-
tions, resulting in the inability to produce the strongly im-
munogenic T-cell antigens ESAT-6 and CFP-10 (13).
Several genotypes of M. microti have been recog-
nized by spacer oligotyping (spoligotyping). The llama-
type (presence of spacers 4–7, 23, 24, 26, 37, 38) and the 
vole-type (only 2 spacers, 37 and 38) have been well de-
scribed; both types are involved in human infections (5,7). 
The international spoligotyping database (SpolDB4) (14) 
includes 40 M. microti strains, 37 of which are from the 
United Kingdom and Western Europe. Although there are 
no published reports of M. microti infections from the Unit-
ed States, 3 of the strains in SpolDB4 are from this country. 
M. microti strains yield broadly similar, high–copy num-
ber ﬁ  ngerprints by the insertion sequence 6110–based re-
striction fragment length polymorphism method (IS6110 
RFLP) (7).
In the 12-year period from 1994 through 2005, we iso-
lated M. microti from 4 humans and from 5 animals (2 cats, 
a llama, a badger, and a ferret). No clinical details were 
available for the animal cases. The animal and human cases 
were from different locations in Scotland. No epidemio-
logic links were apparent. 
The Patients
Patient 1 was a 41-year-old woman in whom spu-
tum smear–positive tuberculosis was diagnosed in 2001. 
She was treated with isoniazid, rifampin, ethambutol, and 
pyrazinamide for 2 months and for 4 months more with 
rifampin and isoniazid. She made good clinical progress, 
but sputum samples remained positive for acid-fast bacilli 
(AFB), although cultures were negative. She was re-treated 
with isoniazid, rifampin, ethambutol, and pyrazinamide 
for 6 months. She became sputum negative and remained 
clinically well at her 6-month follow-up visit. She was not 
immunocompromised. No other patients with tuberculosis 
were identiﬁ  ed in contacts, and no relevant animal contact 
had occurred.
Patient 2 was a 39-year-old man for whom HIV was 
diagnosed in 2003, who had bilateral pulmonary consolida-
tion. The patient lived on a farm. He was initially treated 
with co-trimoxazole for suspected Pneumocystis carinii 
infection, and rifampin, isoniazid, and pyrazinamide were 
added when AFB were seen in the sputum sample. The pa-
tient’s condition deteriorated, and he died despite this drug 
treatment and intensive therapy unit support. No other pa-
tients with tuberculosis were identiﬁ  ed in connection with 
this case. 
Patient 3 was a 76-year-old woman who had received a 
diagnosis of pulmonary tuberculosis in 2005. She made an 
uneventful recovery following standard therapy with iso-
niazid, rifampin, and ethambutol for 2 months, followed by 
rifampin and isoniazid for a further 4 months. She was not 
immunocompromised, and she reported no major animal 
contact. No cases of tuberculosis were identiﬁ  ed in connec-
tion with this patient.
Patient 4 was a 45-year-old woman who was seen 
in 2005 for hemoptysis; a diagnosis of cavitating pulmo-
nary tuberculosis was made. She received treatment with 
isoniazid, rifampin, ethambutol, and pyrazinamide for 2 
months and rifampin and isoniazid for 4 months more. She 
remained unwell, with further hemoptysis, and a residual 
cavity was shown on chest x-ray. Chemotherapy was rein-
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troduced. She was not known to be immunocompromised. 
She had a pet cat and a dog, both in good health. No cases 
of tuberculosis were identiﬁ  ed in contacts.
The laboratory characteristics of the isolates are shown 
in Table 2. Biochemical tests were not possible because of 
sparse growth. Isolates were identiﬁ  ed as M. tuberculosis 
complex by using the Accuprobe culture conﬁ  rmation as-
say (GenProbe, San Diego, CA, USA), and species identiﬁ  -
cation as M. microti was conﬁ  rmed by spoligotyping. Since 
we do not perform drug susceptibility testing using solid 
media, only the 3 strains that grew well in liquid subculture 
were tested. Genotyping data on our isolates are summa-
rized in Table 2 and the Figure.
Conclusions
M. microti infection is widespread in wild small rodent 
populations in the United Kingdom (2). There are sporadic 
reports, all from the United Kingdom and Western Europe, 
of M. microti infection in other mammals. Certain animals, 
such as cats (4,5) and New World camelids domesticated in 
Europe (6), seem to be particularly susceptible. The report-
ed animal cases have all been detected in clinical veterinary 
practice and are unlikely to reﬂ  ect the true ﬁ  eld incidence. 
Difﬁ  culties with laboratory diagnosis probably further con-
tribute to the underestimation of the incidence. M. microti 
grows poorly on traditional solid egg media, and modern 
automated liquid culture techniques do not seem to yield 
better results. Moreover, even when a mycobacterial infec-
tion is diagnosed, routine veterinary diagnostic procedures 
often do not identify the mycobacterium to species level. It 
is likely also that known animal cases are not all formally 
reported in the literature.
The transmission of M. microti to pets, particularly 
cats, is of particular concern. Cats are assumed to acquire 
the M. microti infection from infected wild rodents, but this 
assumption is not supported by the genotyping evidence. 
Most of the strains isolated from cats are genotypically 
very distinct from wild rodent strains, as shown in our cas-
es and in the literature (5). Very little is known about the 
incidence and ecology of M. microti infection in farm and 
domestic animals.
Many of the human patients with M. microti infection 
appear to have no immunologic deﬁ  cits (3 of our 4 patients 
and 3 of the 8 published cases for which relevant clinical 
details were available). However, inherited defects of inter-
leukin receptor function are known to speciﬁ  cally predis-
pose to intracellular infections, particularly mycobacterial 
infection (15). Therefore, some persons with apparently 
normal immunity infected with M. microti may in fact have 
undetected speciﬁ  c immune defects.
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Table 1. Summary of all reported cases of human infections with Mycobacterium microti *
Case-
patient no.  Ref
Age, sex, 
country 
Immune
status Infection site 
Animal
contact Laboratory findings  Outcome
1( 8)4 8  y ,  M ,  
Germany 
HIV positive  Lung None Llama type. Good growth in liquid 
medium. Poor on pyruvate. Drug 
susceptible. Curved bacilli. 
Cured
2( 7,10) 39 y, M, the 
Netherlands
HIV positive  Lung; lymph 
nodes
House mice  Cultures negative; curved bacilli 
in sputum. Vole type on direct 
spoligotyping. 
Cured after 
prolonged
therapy† 
3( 7) 12 y, M, the 
Netherlands
Renal
transplant
Lung
meninges
None Vole type. Other details 
unavailable.
Cured
4( 7) 41 y, M, the 
Netherlands
Renal
transplant
Peritoneal Wild small 
rodents
Vole type. Other details 
unavailable.
Died despite 
therapy 
5( 7) 34 y, M, the 
Netherlands
Normal Lung Lived in 
mobile home
Vole type. Other details 
unavailable.
Cured
6( 9)5 3  y ,  M ,  
Germany 
Normal Lung None Llama type. AFB film negative. 
Liquid culture better than 
pyruvate agar. No growth on 
normal egg media. Fully drug 
susceptible. Noncurved bacilli. 
Cured
7( 9) 58 y, M, 
Germany 
Diabetic Lung None Vole type. Growth on liquid 
culture only (poor). Susceptibility 
not done. Noncurved bacilli. 
Cured
8( 5) Not known; 
England or 
Wales
Not known  Not known  Not known  Llama type.  Not known 
9–12 (5) Not known; 
England or 
Wales
Not known  Not known  Not known  Vole type.  Not known 
13 (11) 69 y, sex not 
known, 
Germany 
Normal Abdominal/
miliary 
Not known  Vole type. Primary culture in 
liquid. Subculture in solid agar. 
Died, despite 
appropriate 
therapy 
*Ref, reference; M, male; AFB, acid-fast bacilli. 
†Three household contacts were found to be tuberculin positive. DISPATCHES
Human-to-human transmission of M. microti infection 
seems rare. In the single instance in which this possibility 
is moot, the secondary cases all occurred in the same mice-
infested household (10). 
Extensive trials of M. microti as a vaccine suggest that 
it lacks virulence for humans with normal immunity. How-
ever, it remains a potential threat to the substantial pool 
of persons with compromised immunity, including the un-
known number who may have genetic defects speciﬁ  cally 
predisposing to mycobacterial infections.
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